2024
County-level racial disparities in prostate cancer–specific mortality from 2005 to 2020
Washington S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J, Cooperberg M. County-level racial disparities in prostate cancer–specific mortality from 2005 to 2020. JNCI Cancer Spectrum 2024, 8: pkae109. PMID: 39495143, PMCID: PMC11631307, DOI: 10.1093/jncics/pkae109.Peer-Reviewed Original ResearchNon-Hispanic blacksRacial disparitiesCancer-specific mortalityCancer outcomesAssociated with lower mortality riskProstate cancer-specific mortalityProstate cancer outcomesNon-Hispanic white patientsLinear mixed models evaluated associationsPrimary care providersSpecific mortalityRadiation oncologist densityLower mortality riskYear of deathBlack-white differencesRace-based disparitiesMortality disparitiesProvider densityCare providersCounty-level dataHospital bedsMortality riskData of menProstate cancer specific mortality riskWhite patients
2023
Prostate cancer disparities among American Indians and Alaskan Natives in the United States
Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023, 115: 413-420. PMID: 36629492, PMCID: PMC10086629, DOI: 10.1093/jnci/djad002.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenAlaska Native patientsCancer-specific mortalityGleason scoreNative patientsDefinitive treatmentWhite patientsProstate cancerTreatment accessAlaska NativesProvider densityHigher prostate-specific antigenAdvanced prostate cancerPatterns of careExternal beam radiationAmerican IndiansProstate cancer disparitiesCounty-level demographicsHealth policy interventionsLower ratesMultivariable adjustmentBaseline characteristicsPathologic factorsWorse survivalProstate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.Peer-Reviewed Original ResearchConceptsProstate cancer riskBRCA1/2 mutation carriersMagnetic resonance imagingProstate cancerMutation carriersCancer riskProspective studyBRCA2 mutationsProstate cancer-specific mortalityProstate specific antigen measurementsCancer-specific mortalityProstate cancer incidenceAggressive clinical behaviorProstate cancer screeningRisk stratification strategiesLong-term resultsSignificant prostate cancerOptimal screening strategyGermline BRCA1/2 mutationsOptimal screening protocolProstate magnetic resonance imagingQuality of lifeBRCA2 tumor suppressor genesOverall survivalDisease characteristics
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancer
2017
Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparitiesRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regressionRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Beard C, Martin N, Feng F, Kim S, Yu J, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Journal Of Clinical Oncology 2017, 35: 18-18. DOI: 10.1200/jco.2017.35.6_suppl.18.Peer-Reviewed Original ResearchProstate cancer-specific mortalityProstate-specific antigenRisk of prostate cancer-specific mortalityProstate-specific antigen screeningProstate cancer outcomesUnited States Preventive Services Task ForceBlack raceMetastatic diseaseCancer outcomesRate of metastatic diseaseCancer-specific mortalityStage of presentationRisk of poor outcomesPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menProstate-specificSEER databaseProstate cancerBlack menPoor outcomeRisk regressionBlack patientsOutcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.
Mahal A, Mahal B, Nguyen P, Yu J. Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Journal Of Clinical Oncology 2017, 35: 198-198. DOI: 10.1200/jco.2017.35.6_suppl.198.Peer-Reviewed Original ResearchProstate cancer-specific mortalityHigh-risk prostate cancerProstate cancerTreatment of high-risk prostate cancerInsurance statusCompeting-risks regression modelsHigh-risk CaPPrivately insured menGray's competing-risks regression modelHigh-risk diseaseCancer-specific mortalityEnd Results ProgramMultivariate logistic regressionMetastatic diseaseNon-black menResults ProgramPrivate insuranceInsured menAfrican American menLogistic regressionMetSOutcomesCancerMenMore-than-additive effect
2016
External validation of a prognostic Gleason grade classification system.
Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. External validation of a prognostic Gleason grade classification system. Journal Of Clinical Oncology 2016, 34: 123-123. DOI: 10.1200/jco.2016.34.2_suppl.123.Peer-Reviewed Original ResearchProstate cancer-specific mortalityRisk of recurrenceGleason grade groupRadical prostatectomyAdjusted pairwise comparisonsGrade groupUCSF cohortGrade diseaseGleason 4Metastatic progressionCox proportional hazards modelGleason classification systemGrade classification systemImmediate radical prostatectomyCancer-specific mortalityAcademic referral centerHigh-grade diseaseIndependent prognostic abilityProportional hazards modelConsecutive PSA valuesDiscrimination of outcomesGleason grading systemGleason grade 3Salvage treatmentReferral center
2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
Mahal B, Muralidhar V, Chen Y, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Trinh Q, Nguyen P. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU International 2015, 118: 95-101. PMID: 26207642, DOI: 10.1111/bju.13239.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityGleason score 5Risk of prostate cancer-specific mortalityGleason score 4Prostate cancerScore 5Increased risk of PCSMGray competing risk regression analysisProstate cancer-specific mortality outcomesProstate cancer-specific mortality ratesScore 4Competing risk regression analysisGleason score 3Gleason score 8Gleason score 9Primary Gleason patternReference group of patientsCancer-specific mortalityAggressive treatment strategiesGroup of patientsRisk regression analysisHighest-risk patientsGleason 4Gleason scoreGleason pattern
2012
A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival
Dosoretz A, Lester-Coll N, Yu J. A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s57. DOI: 10.1016/j.ijrobp.2012.07.355.Peer-Reviewed Original ResearchProstate cancer-specific mortalityDistant metastasis-free survivalMetastasis-free survivalCancer-specific mortalityProstate cancer screeningCancer screeningProstate
2011
Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality
Pomerantz M, Werner L, Xie W, Regan M, Lee G, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh W, Kantoff P, Freedman M. Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality. Cancer Prevention Research 2011, 4: 719-728. PMID: 21367958, PMCID: PMC3811002, DOI: 10.1158/1940-6207.capr-10-0292.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityCancer-specific mortalityProstate-specific antigenProstate cancer risk variantsCancer risk variantsDisease aggressivenessSingle nucleotide polymorphismsGleason scoreProstate cancerAssociated with prostate cancer-specific survivalRisk variantsProstate cancer-specific deathAssociated with prostate cancer aggressivenessProstate cancer-specific survivalDiagnosis of prostate cancerCancer-specific survivalCancer-specific deathProstate cancer aggressivenessMen of European ancestryProstate cancer survivalAssociated with riskD'Amico criteriaClinical parametersClinical outcomesCancer aggressiveness
2006
Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4
Daskivich T, Regan M, Oh W. Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4. Journal Of Urology 2006, 176: 1927-1937. PMID: 17070213, DOI: 10.1016/j.juro.2006.07.002.Peer-Reviewed Original ResearchConceptsProstate specific antigen doubling timeProstate cancer disease statesProstate cancer-specific mortalityDoubling timeProstate cancer databaseCancer-specific mortalityAssessment of prognosisCancer disease statesProstate cancerCancer DatabaseProstateSpecific mortalityClinical experiencePredictive indicatorDisease statesIncorrect managementCliniciansPurposes of patient carePatient carePrognosisMethodological differencesPatientsCancerReviewRegistry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply